Indivior PLC announced that total 2022 expected NR range of $840 million to $900 million (+10% vs. Fiscal Year 2021 at the mid-point); reflects strong SUBLOCADE growth and relative market share stability for SUBOXONE Film, which continues to deviate from industry analogues as a genericized treatment. SUBLOCADE 2022 expected NR range of $360 million to $400 million (+56% vs.

2021 at the mid-point), primarily based on strong penetration and growth in the OHS channel. PERSERIS 2022 expected NR range of $27 million to $32 million (+74% vs. 2021 at the mid-point).